Diametric Capital LP Buys 1,976 Shares of Amedisys, Inc. (NASDAQ:AMED)

Diametric Capital LP lifted its position in Amedisys, Inc. (NASDAQ:AMED) by 26.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,476 shares of the health services provider’s stock after acquiring an additional 1,976 shares during the period. Diametric Capital LP’s holdings in Amedisys were worth $860,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the company. Norges Bank bought a new position in Amedisys during the fourth quarter worth about $83,061,000. Wealthfront Advisers LLC acquired a new stake in shares of Amedisys during the fourth quarter worth about $72,970,000. Pacer Advisors Inc. lifted its holdings in shares of Amedisys by 11,621.9% during the 4th quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider’s stock valued at $50,679,000 after purchasing an additional 553,435 shares in the last quarter. Polar Asset Management Partners Inc. acquired a new position in shares of Amedisys in the 3rd quarter valued at approximately $28,953,000. Finally, Birnam Oak Advisors LP bought a new stake in Amedisys during the 4th quarter worth approximately $15,832,000. Institutional investors and hedge funds own 94.36% of the company’s stock.

Amedisys Stock Down 0.1 %

AMED stock opened at $92.63 on Tuesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The stock has a market capitalization of $3.04 billion, a P/E ratio of 36.76, a P/E/G ratio of 1.78 and a beta of 0.76. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The business has a 50-day moving average of $92.29 and a 200-day moving average of $92.37.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm had revenue of $598.05 million for the quarter, compared to analyst estimates of $602.38 million. On average, sell-side analysts anticipate that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Stephens reaffirmed an “equal weight” rating and issued a $101.00 price target on shares of Amedisys in a research note on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, Amedisys has an average rating of “Hold” and an average target price of $101.00.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.